13F COMBINATION REPORT
Crestline Management, LP
Quarter ended Q2 2025 · Filed August 14, 2025 · Accession 0001315863-25-000627
Total Value
$62.6M
Positions
3
Other Managers
0
Confidential Omitted
No
Holdings (3)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | DENALI THERAPEUTICS INC | DNLI | 3,860,732 | $54.0M | 86.33% |
| 2 | SANA BIOTECHNOLOGY INC | SANA | 2,420,937 | $6.6M | 10.56% |
| 3 | 8X8 INC NEW | 282914100 | 990,580 | $1.9M | 3.10% |